Antidepressant Withdrawal

For two decades, difficulty stopping antidepressants was routinely reframed as relapse — proof the patient still needed the drug. The physiology says otherwise: brains adapt to chronic serotonergic drugs, and removing them produces a recognisable syndrome (dizziness, electric-shock 'brain zaps', nausea, insomnia, agitation) that can begin within days and is distinguishable from relapse by its rapid onset, physical character and quick response to reinstatement. The UK Royal College of Psychiatrists formally changed position in 2019, and NICE guidance now requires clinicians to warn patients before prescribing and to taper slowly when stopping. On the core fact, the patient movement was right and official medicine was late.

The widely cited claim that 56% of users experience withdrawal (with 46% of those describing it as severe) came from a 2019 review criticised for leaning on online surveys of self-selected patients. The most rigorous estimate to date — a 2024 Lancet Psychiatry meta-analysis of 79 studies with over 20,000 patients — found symptoms in about 31% of patients stopping antidepressants and 17% stopping placebo, implying a true drug-attributable incidence near one in six or seven, with severe symptoms in roughly 3%. Both sides accept withdrawal exists; the battle is over prevalence, and it matters because the answer calibrates everything from consent conversations to service design.

A minority of patients report symptoms lasting months or years after stopping — protracted withdrawal — and this is where evidence is thinnest. Long-term follow-up studies barely exist, mechanisms are speculative, and prevalence estimates range from rare to several percent depending entirely on sampling. Online communities documenting the phenomenon predate its academic recognition by a decade, an uncomfortable echo of the original denial. Honest position: protracted withdrawal is credibly reported, biologically plausible, unquantified, and a research priority — not a settled epidemic and not imaginary.

Receptor-occupancy imaging shows the relationship between dose and effect is hyperbolic: at low doses, small milligram reductions produce large drops in receptor occupancy. This explains the classic clinical observation that the final milligrams are the hardest to stop, and it is why guidance has shifted from linear tapers ('halve, then stop') to hyperbolic ones — progressively smaller absolute reductions, sometimes over months, using liquid formulations or tapering strips to reach doses far below the smallest tablet. The 2023 Maudsley Deprescribing Guidelines codified this approach, moving it from patient forums into mainstream reference texts in under a decade.

Roughly one in six adults in England is prescribed an antidepressant in a given year — over 8 million people — with similar proportions across much of the West, and median treatment durations have stretched from months to years. Even a one-in-six withdrawal incidence applied to populations this size produces millions of affected patients, most managed (or mismanaged) in primary care in consultations too short for careful tapering. Deprescribing infrastructure — clinician training, liquid formulations, follow-up capacity — has lagged prescribing volume by decades, and that asymmetry, not any single study, is the system-level failure.

Never stop abruptly. Plan discontinuation with a prescriber, expect the taper to be slower the longer the treatment and the higher the dose, and expect the last portion to require the smallest steps — hyperbolic, not linear. Reinstating a small dose usually relieves severe withdrawal quickly, which is also the practical test distinguishing withdrawal from relapse (relapse builds over weeks and responds slowly). Withdrawal being real does not mean antidepressants were the wrong choice, and stopping is not obligatory: the goal is informed, unhurried decisions in both directions.